BR112021017780A2 - Métodos de terapia anti-tumor - Google Patents

Métodos de terapia anti-tumor

Info

Publication number
BR112021017780A2
BR112021017780A2 BR112021017780A BR112021017780A BR112021017780A2 BR 112021017780 A2 BR112021017780 A2 BR 112021017780A2 BR 112021017780 A BR112021017780 A BR 112021017780A BR 112021017780 A BR112021017780 A BR 112021017780A BR 112021017780 A2 BR112021017780 A2 BR 112021017780A2
Authority
BR
Brazil
Prior art keywords
tumor
therapy methods
tumor therapy
dose
subject
Prior art date
Application number
BR112021017780A
Other languages
English (en)
Inventor
Shifra Fain-Shmueli
Rachmilewitz Minei Tamar
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of BR112021017780A2 publication Critical patent/BR112021017780A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Abstract

métodos de terapia anti-tumor. a invenção provê métodos para a indução ou aumento de uma resposta antitumoral em um indivíduo apresentando um tumor, compreendendo a administração ao indivíduo uma dose preparatória de um vetor que compreende um gene quimera fas ligado operacionalmente a um promotor específico de célula endotelial, onde a dose preparatória do vetor é administrada antes da remoção cirúrgica do tumor ou de parte deste.
BR112021017780A 2019-03-13 2020-03-12 Métodos de terapia anti-tumor BR112021017780A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817735P 2019-03-13 2019-03-13
PCT/IB2020/052260 WO2020183424A1 (en) 2019-03-13 2020-03-12 Methods of anti-tumor therapy

Publications (1)

Publication Number Publication Date
BR112021017780A2 true BR112021017780A2 (pt) 2022-02-01

Family

ID=70058427

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017780A BR112021017780A2 (pt) 2019-03-13 2020-03-12 Métodos de terapia anti-tumor

Country Status (12)

Country Link
US (1) US20220154212A1 (pt)
EP (1) EP3937959A1 (pt)
JP (1) JP2022524321A (pt)
KR (1) KR20210139329A (pt)
CN (1) CN113784730A (pt)
AU (1) AU2020234098A1 (pt)
BR (1) BR112021017780A2 (pt)
CA (1) CA3131936A1 (pt)
IL (1) IL286198A (pt)
MX (1) MX2021011084A (pt)
SG (1) SG11202109173UA (pt)
WO (1) WO2020183424A1 (pt)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2286330C (en) 1997-04-07 2008-06-10 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
DK1487856T3 (da) 2002-03-04 2010-10-18 Imclone Llc KDR-specifikke humane antistoffer og deres anvendelse
ES2523457T3 (es) 2004-11-18 2014-11-26 Imclone Llc Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular
ES2572356T3 (es) 2007-11-09 2016-05-31 Peregrine Pharmaceuticals Inc Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
SG10201500048SA (en) 2010-01-05 2015-03-30 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
SG10201500013SA (en) 2010-01-05 2015-03-30 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
US20130320253A1 (en) 2010-10-18 2013-12-05 Total Research & Trchnogy Feluy Expandable vinyl aromatic polymers
PT2908865T (pt) * 2012-10-17 2019-01-11 Vascular Biogenics Ltd Adenovírus que expressa uma quimera de fas e sua utilização em métodos de tratamento de cancro
WO2014118643A2 (en) * 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent

Also Published As

Publication number Publication date
EP3937959A1 (en) 2022-01-19
US20220154212A1 (en) 2022-05-19
KR20210139329A (ko) 2021-11-22
WO2020183424A1 (en) 2020-09-17
AU2020234098A1 (en) 2021-09-16
SG11202109173UA (en) 2021-09-29
MX2021011084A (es) 2021-10-22
JP2022524321A (ja) 2022-05-02
CN113784730A (zh) 2021-12-10
CA3131936A1 (en) 2020-09-17
IL286198A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112019024674A2 (pt) Inibidores covalentes da kras
BR112019000598A2 (pt) rna para terapia de câncer
WO2017079746A3 (en) Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
BR112015026095A2 (pt) métodos para controlar a dosagem de uma droga antitumoral administrada a um paciente com câncer, para administração de pelo menos uma droga antitumoral em duas doses separadas em um paciente com câncer e para seleção de pelo menos uma droga antitumoral
BR112017000703A2 (pt) métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
BR112021017375A2 (pt) Composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer
BR112016025764A2 (pt) vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112015024537A2 (pt) terapia de câncer
BR112016021985A8 (pt) formulação farmacêutica e composto
BR112018072988A2 (pt) irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula
MX2018015172A (es) Metodos para tratar cancer pancreatico.
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]